Cited by 369Treatment of Major DepressionPsychotherapy Techniques and ApplicationsAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.

Personalized Medicine for Depression: Can We Match Patients With Treatments?

Open access

Simon, Gregory E., Perlis, Roy H.·2010·American Journal of Psychiatry

DOI 10.1176/appi.ajp.2010.09111680PMC PMC3723328

Open this paper in CoChat — free account

Abstract

OBJECTIVE: Response to specific depression treatments varies widely among individuals. Understanding and predicting that variation could have great benefits for people living with depression. METHOD: The authors describe a conceptual model for identifying and evaluating evidence relevant to personalizing treatment for depression. They review evidence related to three specific treatment decisions: choice between antidepressant medication and psychotherapy, selection of a specific antidepressant medication, and selection of a specific psychotherapy. They then discuss potential explanations for negative findings as well as implications for research and clinical practice. RESULTS: Many previous studies have examined general predictors of outcome, but few have examined true moderators (predictors of differential response to alternative treatments). The limited evidence indicates that some specific clinical characteristics may inform the choice between antidepressant medication and psychotherapy and the choice of specific antidepressant medication. Research to date does not identify any biologic or genetic predictors of sufficient clinical utility to inform the choice between medication and psychotherapy, the selection of specific medication, or the selection of a specific psychotherapy. CONCLUSIONS: While individuals vary widely in response to specific depression treatments, the variability remains largely unpredictable. Future research should focus on identifying true moderator effects and should consider how response to treatments varies across episodes. At this time, our inability to match patients with treatments implies that systematic follow-up assessment and adjustment of treatment are more important than initial treatment selection.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2010.09111680

Cites

90 of 90 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The moderator-mediator variable distinction in social psychological research: Conceptual, strategic, and statistical considerations
Baron, R. M., & Kenny, D. A. (1986) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.51.6.1173 · Cited by 91,532
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Mediators and Moderators of Treatment Effects in Randomized Clinical Trials
Kraemer, H. C., Wilson, G. T., Fairburn, C. G., & Agras, W. S. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.877 · Cited by 2,562
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J. (2010) · JAMA · doi:10.1001/jama.2009.1943 · Cited by 2,009
Replication validity of genetic association studies
Ioannidis, J. P. A., Ntzani, E., Trikalinos, T. A., & Contopoulos‐Ioannidis, D. G. (2001) · Nature Genetics · doi:10.1038/ng749 · Cited by 1,834
Problems of Spectrum and Bias in Evaluating the Efficacy of Diagnostic Tests
Ransohoff, D. F., & Feinstein, A. R. (1978) · New England Journal of Medicine · doi:10.1056/nejm197810262991705 · Cited by 1,739
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654 · cited 1×
“And on average, different antidepressants show equal or similar effi cacy (4, 5).”
Background
Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression.
Dimidjian, S., Hollon, S. D., Dobson, K. S., Schmaling, K. B., Kohlenberg, R. J., Addis, M. E., Gallop, R., McGlinchey, J. B., Markley, D. K., Gollan, J. K., et al. (2006) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.74.4.658 · Cited by 1,607
Collaborative Care for Depression: A Cumulative Meta-analysis and Review of Longer-term Outcomes
Gilbody, S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.21.2314 · Cited by 1,340
The quality of care for depressive and anxiety disorders in the United States
Young, A. S., Klap, R., Sherbourne, C. D., & Wells, K. B. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.1.55 · Cited by 1,061
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · cited 2×
“For example, among patients who do not benefi t from initial treatment with one antidepressant, up to one-half experience signifi cant improvement after switching to an alternative medication (8), adding a second medication (9), or adding psychotherapy (10).”
Background
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Cognitive Therapy vs Medications in the Treatment of Moderate to Severe Depression
DeRubeis, R. J., Hollon, S. D., Amsterdam, J. D., Shelton, R. C., Young, P. R., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Gladis, M. M., Brown, L. L., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.409 · Cited by 989
Distributed Disturbances in Brain Structure and Function in Schizophrenia
Lewis, D. A. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.1 · Cited by 971
Common Genetic Variation and Human Traits
Goldstein, D. B. (2009) · New England Journal of Medicine · doi:10.1056/nejmp0806284 · Cited by 918
Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma
Nemeroff, C. B., Heim, C. M., Thase, M. E., Klein, D. N., Rush, A. J., Schatzberg, A. F., Ninan, P. T., McCullough, J. P., Weiss, P. M., Dunner, D. L., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2336126100 · Cited by 829
Educational and Organizational Interventions to Improve the Management of Depression in Primary Care: A Systematic Review
Gilbody, S., Whitty, P., Grimshaw, J., & Thomas, R. (2003) · JAMA · doi:10.1001/jama.289.23.3145 · Cited by 749
Evidence‐Based Medicine, Heterogeneity of Treatment Effects, and the Trouble with Averages
Kravitz, R. L., Duan, N., & Braslow, J. T. (2004) · Milbank Quarterly · doi:10.1111/j.0887-378x.2004.00327.x · Cited by 613 · cited 1×
“But the fact that treatments have similar effi cacy on average does not imply that treatment selection is unimportant (6, 7).”
Background
Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association.
(2000) · PubMed · Cited by 509
Severity of Depression and Response to Antidepressants and Placebo: An Analysis of the Food and Drug Administration Database
Khan, A., Leventhal, R. M., Khan, S. R., & Brown, W. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00007 · Cited by 456
Medications Versus Cognitive Behavior Therapy for Severely Depressed Outpatients: Mega-Analysis of Four Randomized Comparisons
DeRubeis, R. J., Gelfand, L. A., Tang, T. Z., & Simons, A. D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1007 · Cited by 449
Telephone Psychotherapy and Telephone Care Management for Primary Care Patients Starting Antidepressant Treatment: A Randomized Controlled Trial
Simon, G. E., Ludman, E. J., Tutty, S., Operskalski, B., & Korff, M. V. (2004) · JAMA · doi:10.1001/jama.292.8.935 · Cited by 395
Self-citation
Genome-Wide Pharmacogenetics of Antidepressant Response in the GENDEP Project
Uher, R., Perroud, N. A., Ng, M., Hauser, J., Henigsberg, N., Maier, W., Mors, O. N., Placentino, A., Rietschel, M., Souery, D., et al. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09070932 · Cited by 357
Prediction of Response to Medication and Cognitive Therapy in the Treatment of Moderate to Severe Depression.
Fournier, J. C., DeRubeis, R. J., Shelton, R. C., Hollon, S. D., Amsterdam, J. D., & Gallop, R. (2009) · Journal of Consulting and Clinical Psychology · doi:10.1037/a0015401 · Cited by 340
Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report
Thase, M. E., Friedman, E. S., Biggs, M. M., Wisniewski, S. R., Trivedi, M. H., Luther, J. F., Fava, M., Nierenberg, A. A., McGrath, P. J., Warden, D., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.5.739 · Cited by 332 · cited 1×
“For example, among patients who do not benefi t from initial treatment with one antidepressant, up to one-half experience signifi cant improvement after switching to an alternative medication (8), adding a second medication (9), or adding psychotherapy (10).”
Background
Moderators of Treatment Outcomes: Clinical, Research, and Policy Importance
Kraemer, H. C., Frank, E., & Kupfer, D. J. (2006) · JAMA · doi:10.1001/jama.296.10.1286 · Cited by 310
A Genomewide Association Study Points to Multiple Loci That Predict Antidepressant Drug Treatment Outcome in Depression
Ising, M., Lucae, S., Binder, E. B., Bettecken, T., Uhr, M., Ripke, S., Kohli, M. A., Hennings, J. M., Horstmann, S., Kloiber, S. M., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.95 · Cited by 308
The FKBP5 gene in depression and treatment response – an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) cohort
Lekman, M., Laje, G., Charney, D., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Lipsky, R., Wisniewski, S. R., Manji, H., McMahon, F. J., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.10.026 · Cited by 284
Pharmacogenetics of Antidepressant Medication Intolerance
Murphy, G. M., Kremer, C. M. E., Rodrigues, H. E., & Schatzberg, A. F. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.10.1830 · Cited by 284
Comparative Benefits and Harms of Second-Generation Antidepressants: Background Paper for the American College of Physicians
Gartlehner, G., Gaynes, B. N., Hansen, R. A., Thieda, P., DeVeaugh‐Geiss, A., Krebs, E. E., Moore, C. G., Morgan, L. C., & Lohr, K. N. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-10-200811180-00008 · Cited by 240
Sequence Analysis of the Serotonin Transporter and Associations with Antidepressant Response
Kraft, J. B., Slager, S. L., McGrath, P. J., & Hamilton, S. P. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.048 · Cited by 224
Association Between a Functional Serotonin Transporter Promoter Polymorphism and Citalopram Treatment in Adult Outpatients With Major Depression
Hu, X., Rush, A. J., Charney, D. S., Wilson, A. F., Sorant, A. J. M., Papanicolaou, G., D, M. F. M., Trivedi, M. H., Wisniewski, S. R., Laje, G., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.7.783 · Cited by 218
Genetic Markers of Suicidal Ideation Emerging During Citalopram Treatment of Major Depression
Laje, G., Paddock, S., Manji, H. K., Rush, A. J., Wilson, A. F., Charney, D. S., & McMahon, F. J. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06122018 · Cited by 213
Personalized Medicine in the Era of Genomics
Burke, W., & Psaty, B. M. (2007) · JAMA · doi:10.1001/jama.298.14.1682 · Cited by 208
Monoamine Transporter Gene Polymorphisms and Antidepressant Response in Koreans With Late-Life Depression
Kim, H. R., Lim, S., Kim, S., Kim, J., Chang, Y. H., Carroll, B. J., & Kim, D. K. (2006) · JAMA · doi:10.1001/jama.296.13.1609 · Cited by 202
Association of GRIK4 With Outcome of Antidepressant Treatment in the STAR*D Cohort
Paddock, S., Laje, G., Charney, D. S., Rush, A. J., Wilson, A. F., Sorant, A. J. M., Lipsky, R. H., Wisniewski, S. R., Manji, H., & McMahon, F. J. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111790 · Cited by 195
The role of avoidance and obsessiveness in matching patients to cognitive and interpersonal psychotherapy: empirical findings from the treatment for depression collaborative research program.
Barber, J., & Muenz, L. (1996) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.64.5.951 · Cited by 194
Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder
Hong, C.-J., Chen, T., Yu, Y. W.-Y., & Tsai, S.-J. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500340 · Cited by 189
Selecting Among Second-Step Antidepressant Medication Monotherapies
Rush, A. J., Wisniewski, S. R., Warden, D., Luther, J. F., Davis, L. L., D, M. F. M., Nierenberg, A. A., & Trivedi, M. H. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.8.870 · Cited by 178
Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment
Perlis, R. H., Mischoulon, D., Smoller, J. W., Wan, Y. Y., Lamon‐Fava, S., Lin, K.-M., Rosenbaum, J. F., & D, M. F. M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00424-4 · Cited by 177
Self-citation
Personality and Differential Treatment Response in Major Depression: A Randomized Controlled Trial Comparing Cognitive-Behavioural Therapy and Pharmacotherapy
Bagby, R. M., Quilty, L. C., Segal, Z. V., McBride, C., Kennedy, S. H., & Costa, P. T. (2008) · The Canadian Journal of Psychiatry · doi:10.1177/070674370805300605 · Cited by 172
Attachment as moderator of treatment outcome in major depression: A randomized control trial of interpersonal psychotherapy versus cognitive behavior therapy.
McBride, C., Atkinson, L. R., Quilty, L. C., & Bagby, R. M. (2006) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.74.6.1041 · Cited by 172
Patient Preference as a Moderator of Outcome for Chronic Forms of Major Depressive Disorder Treated With Nefazodone, Cognitive Behavioral Analysis System of Psychotherapy, or Their Combination
Kocsis, J. H., Leon, A. C., Markowitz, J. C., Manber, R., Arnow, B. A., Klein, D. N., & Thase, M. E. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04371 · Cited by 172
Association of GRIK4 With Outcome of Antidepressant Treatment in the STAR*D Cohort
Ballenger, J. C. (2009) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)79086-8 · Cited by 166
Pragmatic randomised controlled trials in psychiatry
Hotopf, M., Churchill, R., & Lewis, G. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.3.217 · Cited by 165
Treatment Process and Outcomes for Managed Care Patients Receiving New Antidepressant Prescriptions From Psychiatrists and Primary Care Physicians
Simon, G. E., Korff, M. V., Rutter, C. M., & Peterson, D. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.4.395 · Cited by 160 · cited 2×
“Of patients initiating antidepressant treatment, as many as one-half will not return for follow-up visits (11, 12).”
BackgroundSelf-citation
Prediction of Antidepressant Response to Milnacipran by Norepinephrine Transporter Gene Polymorphisms
Yoshida, K., Takahashi, H., Higuchi, H., Kamata, M., Ito, K., Sato, K., Naito, S., Shimizu, T., Itoh, K., Inoue, K., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1575 · Cited by 160
Which depressed patients will respond to interpersonal psychotherapy? The role of abnormal EEG sleep profiles
Thase, M. E., Buysse, D. J., Frank, E., Cherry, C. R., Cornes, C. L., Mallinger, A. G., & Kupfer, D. J. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.502 · Cited by 157
The role of avoidance and obsessiveness in matching patients to cognitive and interpersonal psychotherapy: Empirical findings from the Treatment for Depression Collaborative Research Program.
Barber, J. P., & Muenz, L. R. (1996) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.64.5.951 · Cited by 151
The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression
Szegedi, A., Rujescu, D., Tadić, A., Müller, M., Kohnen, R., Stassen, H. H., & Dahmen, N. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500289 · Cited by 149
The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder
Durham, L. K., Webb, S., Milos, P. M., Clary, C., & Seymour, A. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1562-3 · Cited by 149
Association Between Treatment-Emergent Suicidal Ideation With Citalopram and Polymorphisms Near Cyclic Adenosine Monophosphate Response Element Binding Protein in the STAR*D Study
Perlis, R. H., Purcell, S., D, M. F. M., Fagerness, J. A., Rush, A. J., Trivedi, M. H., & Smoller, J. W. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.689 · Cited by 149
Self-citation
Temperament, character and personality disorders as predictors of response to interpersonal psychotherapy and cognitive-behavioural therapy for depression
Joyce, P. R., McKenzie, J. M., Carter, J. D., Rae, A. M., Luty, S. E., FRAMPTON, C. M. A., & Mulder, R. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.106.024737 · Cited by 140 · cited 3×
“(17) Personality disorder (primarily avoidant and borderline) CBT (N=76) Interpersonal therapy (N=83) Decline in Montgomery-Åsberg Depression Rating Scale score (%) 58% vs.”
Background
Antidepressant medicationsv.cognitive therapy in people with depression with or without personality disorder
Fournier, J. C. J., DeRubeis, R. J., Shelton, R. C., Gallop, R., Amsterdam, J. D., & Hollon, S. D. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.037234 · Cited by 128
Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders
Yu, Y. W. ‐., Tsai, S., Liou, Y., Hong, C., & Chen, T. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.12.004 · Cited by 124
How to evaluate a diagnostic marker test. Lessons from the rise and fall of dexamethasone suppression test
Nierenberg, A. A. (1988) · JAMA · doi:10.1001/jama.259.11.1699 · Cited by 121
Efficacy of Bupropion and the Selective Serotonin Reuptake Inhibitors in the Treatment of Major Depressive Disorder With High Levels of Anxiety (Anxious Depression)
Papakostas, G. I., Stahl, S. M., Krishen, A., Seifert, C. A., Tucker, V. L., Goodale, E. P., & D, M. F. M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0812 · Cited by 117
Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder
Papakostas, G. I., & D, M. F. M. (2008) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2008.10.4/gipapakostas · Cited by 115
A Placebo-Controlled Study of Fluoxetine Versus Imipramine in the Acute Treatment of Atypical Depression
McGrath, P. J., Stewart, J. W., Janal, M. N., Petkova, E., Quitkin, F. M., & Klein, D. F. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.3.344 · Cited by 114
Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein β3 subunit as predictors of response to fluoxetine and nortriptyline
Joyce, P. R., Mulder, R., Luty, S. E., McKenzie, J. M., Miller, A. L., Rogers, G. R., & Kennedy, M. A. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003663 · Cited by 107
Efficacy of Combined Therapy and Pharmacotherapy for Depressed Patients with or without Personality Disorders
Kool, S., Dekker, J., Duijsens, I. J., de Jonghe, F., & Puite, B. (2003) · Harvard Review of Psychiatry · doi:10.1080/10673220303950 · Cited by 107
Genetic and Clinical Predictors of Sexual Dysfunction in Citalopram-Treated Depressed Patients
Perlis, R. H., Laje, G., Smoller, J. W., D, M. F. M., Rush, A. J., & McMahon, F. J. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.4 · Cited by 99
Self-citation
Serotonin 2A −1438 G/A and G-Protein Beta3 Subunit C825T Polymorphisms in Patients with Depression and SSRI-Associated Sexual Side-Effects
Bishop, J. R., Moline, J., Ellingrod, V. L., Schultz, S. K., & Clayton, A. H. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301090 · Cited by 98
When is Pharmacogenetic Testing for Antidepressant Response Ready for the Clinic? A Cost-effectiveness Analysis Based on Data from the STAR*D Study
Perlis, R. H., Patrick, A. R., Smoller, J. W., & Wang, P. S. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.50 · Cited by 82
Self-citation
Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy
Bellino, S., Zizza, M., Rinaldi, C., & Bogetto, F. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100707 · Cited by 81
Hypothalamic-pituitary-adrenocortical activity and response to cognitive behavior therapy in unmedicated, hospitalized depressed patients
Thase, M. E., Dubé, S., Bowler, K., Howland, R. H., Myers, J. E., Friedman, E. S., & Jarrett, D. B. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.7.886 · Cited by 80
The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine
Yoshida, K., Higuchi, H., Kamata, M., Takahashi, H., Inoue, K., Suzuki, T., Itoh, K., & Ozaki, N. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106072192 · Cited by 80
Variation in Catechol-O-Methyltransferase Is Associated with Duloxetine Response in a Clinical Trial for Major Depressive Disorder
Perlis, R. H., Fijal, B. A., Adams, D. H., Sutton, V. K., Trivedi, M. H., & Houston, J. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.10.002 · Cited by 78
Self-citation
Clinical guidelines for the treatment of depressive disorders, I. Definitions, prevalence, and health burden.
Parikh, S. V., & Lam, R. W. M. (2001) · PubMed · Cited by 73
Urinary MHPG Levels and Tricyclic Antidepressant Drug Selection
Cobbin, D. M. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780100081007 · Cited by 69
Predictive Value of Symptoms of Atypical Depression
McGrath, P. J., Stewart, J. W., Harrison, W. M., Ocepek‐Welikson, K., Rabkin, J. G., NUNES, E. N., Wager, S., TRICAMO, E., Quitkin, F. M., & Klein, D. F. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199206000-00009 · Cited by 63
Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors
Smits, K. M., Smits, L. J. M., Peeters, F. P. M. L., Schouten, J., Janssen, R. G. J. H., Smeets, H. J. M., van Os, J., & Prins, M. H. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328014822a · Cited by 62
The MAOA T941G polymorphism and short‐term treatment response to mirtazapine and paroxetine in major depression
Tadić, A., Müller, M. J., Rujescu, D., Kohnen, R., Stassen, H. H., Dahmen, N., & Szegedi, A. (2006) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30462 · Cited by 62
Choosing a First-Line Antidepressant
Simon, G. (2001) · JAMA · doi:10.1001/jama.286.23.3003 · Cited by 60 · cited 1×
“But the fact that treatments have similar effi cacy on average does not imply that treatment selection is unimportant (6, 7).”
BackgroundSelf-citation
Influence of the tyrosine hydroxylase val81met polymorphism and catechol‐O‐methyltransferase val158met polymorphism on the antidepressant effect of milnacipran
Yoshida, K., Higuchi, H., Takahashi, H., Kamata, M., Sato, K., Inoue, K., Suzuki, T., Itoh, K., & Ozaki, N. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.907 · Cited by 56
Pharmacogenetic Testing in the Clinical Management of Schizophrenia
Perlis, R. H., Ganz, D. A., Avorn, J., Schneeweiß, S., Glynn, R. J., Smoller, J. W., & Wang, P. S. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000177553.59455.24 · Cited by 52
Self-citation
Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy
Bellino, S., Zizza, M., Rinaldi, C., & Bogetto, F. (2007) · The Canadian Journal of Psychiatry · doi:10.1177/070674370705201106 · Cited by 45 · cited 3×
“(18) Borderline personality disorder Cognitive therapy (N=12) Interpersonal therapy (N=14) Mean HAM-D posttreatment score 13.”
Background
Clinical Guidelines for the Treatment of Depressive Disorders I. Definitions Prevalence Health Burden
Parikh, S. V., Lam, R. W. M., & the CANMAT Depression Work Group (2001) · The Canadian Journal of Psychiatry · doi:10.1177/070674372001460101001 · Cited by 43
Drug-Gene Interactions between Genetic Polymorphisms and Antihypertensive Therapy
Schelleman, H., Stricker, B. H. C., de Boer, A., Kroon, A. A., Verschuren, W. M. M., van Duijn, C. M., Psaty, B. M., & Klungel, O. H. (2004) · Drugs · doi:10.2165/00003495-200464160-00006 · Cited by 42
Psychobiological correlates of poor response to cognitive behavior therapy: potential indications for antidepressant pharmacotherapy.
Thase, M. E., Simons, A. D., & Reynolds, C. F. (1993) · PubMed · Cited by 42
Select comorbid personality disorders and the treatment of chronic depression with nefazodone, targeted psychotherapy, or their combination
Maddux, R. E., Riso, L. P., Klein, D. N., Markowitz, J. C., Rothbaum, B. O., Arnow, B. A., Manber, R., Blalock, J. A., Keitner, G. I., & Thase, M. E. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.01.010 · Cited by 40
Clinically Responsible Genetic Testing in Neuropsychiatric Patients: A Bridge Too Far and Too Soon
BRAFF, D. L., & Freedman, R. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08050717 · Cited by 37
The Alpha 2A-Adrenergic Receptor Gene Polymorphism Modifies Antidepressant Responses to Milnacipran
Wakeno, M., Kato, M., Okugawa, G., Fukuda, T., Hosoi, Y., Takekita, Y., Yamashita, M., Nonen, S., Azuma, J., & Kinoshita, T. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818455fc · Cited by 32
A monoamine oxidase B gene variant and short-term antidepressant treatment response
Tadić, A., Rujescu, D., Müller, M. J., Kohnen, R., Stassen, H. H., Dahmen, N., & Szegedi, A. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.05.015 · Cited by 24
Cytochrome P450 genotyping and antidepressants
Perlis, R. H. (2007) · BMJ · doi:10.1136/bmj.39169.547512.80 · Cited by 18
Self-citation
Rational antidepressant selection: applying evidence-based medicine to complex real-world patients.
Zetin, M., Hoepner, C. T., & Bjornson, L. (2006) · PubMed · Cited by 17
Failure of urinary MHPG levels to predict treatment response in patients with unipolar depression
Janicak, P. G., Davis, J. M., Chan, C. C. H., Altman, E., & Hedeker, D. (1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.11.1398 · Cited by 15
Differential Responses to a Single Antidepressant in Recurrent Episodes of Major Depression
Rémillard, A. J., Blackshaw, S. L., & Dangor, A. (1994) · Psychiatric Services · doi:10.1176/ps.45.4.359 · Cited by 12
Biological predictors of treatment response in affective illness
Perlis, R. H., Iosifescu, D. V., & Renshaw, P. F. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(02)00112-0 · Cited by 10
Self-citation
Drs. Janicak and Davis Reply
Janicak, P. G., & Davis, J. M. (1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.1.121-a · Cited by 7

Research works printed but not linked: 4

Thase ME, 1993, Psychopharmacol Bull, 29, 293
Zetin M, 2006, Psychopharmacol Bull, 39, 38
Remillard A, 1994, Hosp Community Psychiatry, 45, 359
10.1001/jama.1988.03720110061036 · DOI · Paper page

Sorted by citations

Childhood Maltreatment Predicts Unfavorable Course of Illness and Treatment Outcome in Depression: A Meta-Analysis
Nanni, V., Uher, R., & Danese, A. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11020335 · Cited by 1,480
Time for united action on depression: a Lancet–World Psychiatric Association Commission
Herrman, H., Patel, V., Kieling, C., Berk, M., Buchweitz, C., Cuijpers, P., Furukawa, T. A., Kessler, R. C., Kohrt, B. A., Maj, M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02141-3 · Cited by 1,104
The Biological Effects of Childhood Trauma
De Bellis, M. D., & Zisk, A. (2014) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2014.01.002 · Cited by 892
“important new tool for novel approaches to treatments, such as personalized medicine.(58) Several of these mediation and moderation mechanisms for the biological effects of trauma on the developing child can be found in a previously published critical review by De Bellis,(13) and 12 updated mechanisms are discussed la…”
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842
“…profile of the depressed patient, psychological treatment may be best administered after initiating pharmacotherapy, and in this context clinical features such as melancholic features that may predict better response to SSRIs than CBT should be taken into consideration (Simon and Perlis, 2010).”
Background
A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300059 · Cited by 580

See all 369

Authors: Simon, G. E., & Perlis, R. H.
Affiliations: Kaiser Permanente Washington Health Research Institute (US)
ORCID: Simon, Gregory E.
Perlis, Roy H.
Venue: American Journal of Psychiatry
Publisher: American Psychiatric Association Publishing
Published: 2010-12
Volume: 167
Issue: 12
Pages: 1445-1455
ISSN: 0002-953X (ISSN-L)
1535-7228
DOI: 10.1176/appi.ajp.2010.09111680
PMC: PMC3723328
OpenAlex: W2148933229
Semantic Scholar: ca7063c77ba1833df2d5629f27cb2392af0da971
Cited by: 365
References: 89
Citations by year: 2026: 17 · 2025: 16 · 2024: 34 · 2023: 21 · 2022: 29 · 2021: 29 · 2020: 30 · 2019: 24 · 2018: 21 · 2017: 17 · 2016: 25 · 2015: 24 · 2014: 25 · 2013: 17 · 2012: 26
FWCI: 1.87
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: American Journal of Psychiatry (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Eli Lilly and Company
National Institute of Mental Health (P20MH068572, R01MH085930, R01MH086026)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords: depression, personalized medicine, treatment response variability, antidepressants, psychotherapy, treatment selection, treatment moderators, predictors of treatment outcome, genetic predictors, treatment modification
MeSH terms: Antidepressive Agents, Clinical Trials as Topic, Decision Support Techniques, Depression, Humans, Psychotherapy, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Personalized Medicine for Depression: Can We Match Patients With Treatments?

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks